Study of Sorafenib, Gemcitabine, and Cisplatin in Advanced Hepatocellular Carcinoma (HCC)
Status:
Withdrawn
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
This study will look at the safety and efficacy of treating advanced hepatocellular carcinoma
in patients who have not yet received systemic chemotherapy. Previous local treatment of
hepatic lesions is permitted The treatment will use a combination of three FDA approved
chemotherapy drugs, Gemcitabine, Cisplatin and Sorafenib. Sorafenib is FDA approved for the
treatment of hepatocellular cancer, gemcitabine and cisplatin are not approved for the
treatment of hepatocellular cancer.